BASIC AND CLINICAL STUDIES ON NY-198 IN OPHTHALMOLOGY
スポンサーリンク
概要
- 論文の詳細を見る
We performed basic and clinical studies on NY-198, a new quinoline derivative for oral use, in the field of ophthalmology.<BR>1) NY-198 was administered orally in a daily dose of 300mg or 600mg to 17 patients with various eye infections, including hordeolum 6, acute dacryocystitis 2, meibomitis 7, corneal ulcer 1, and lid abscess 1. Clinical results were excellent in 10, good in 6, and fair in 1, the total efficacy rate being 94.4%.<BR>2) We measured NY-198 concentrations in both serum and tear fluid 0.5, 1.0, 2.0, 3.0, 4.0, and 6.0 hours after a single oral dose of 200mg. The average peak serum and tear levels were 1.25μg/ml±0.14 and 0.98μg/ml±0.27 at 2 h after treatment. This tear level was considered effective in external eye infections (meibomitis, hordeolum, dacryocystitis, etc.) caused by<I>S. aureus</I>.<BR>3) No side-effects or abnormal clinical laboratory findings due to NY-198 were observed, with the exception of stomach-ache in one patient.
- 公益社団法人 日本化学療法学会の論文
公益社団法人 日本化学療法学会 | 論文
- DISPOSITION OF 7432-8 IN RATS (I)
- CLINICAL STUDIES ON T-1220 IN SURGICAL CASES
- CLINICAL STUDIES OF PIVALOYLOXYMETHYL D-α-AMINOBENZYL-PENICILLINATE HYDROCHLORIDE IN SURGICAL INFECTIONS
- STUDIES ON AC-1370
- Primary treatment with a combination of cyclophosphamide, vincristine, and dacarbazine for recurrent malignant pheochromocytoma: A case report.